COMPANY RESULTS

AIA Group (1299 HK)

1H23: VONB In Line; Margin Slumps A Concern

AIA's 1H23 VONB came in largely within our estimates, driven by the return of MCV in Hong Kong. The huge margin compression in 1H23 was due to the hot sale of lowmargin participating products. AIA continues to gain growth momentum in ASEAN but the company faces slower growth in China. We trim our 2023/24 EV per share forecast by 5% after revising our long-term VONB margin and VONB growth assumptions. Maintain BUY with a lower target price of HK\$95.00.

1H23 RESULTS

| | VONB Margin % | | | Val | ue of new busines | s (VONB) |
|-------------------------|---------------|-------|-------------|-------|-------------------|----------------|
| Year to 31 Dec (US\$ m) | 1H23 | 1H22 | yoy ppt chg | 1H23 | yoy chg (AER)* | yoy chg (CER)* |
| Hong Kong | 58.5% | 69.3% | -10.8 ppt | 681 | 111% | 111% |
| Thailand | 91.6% | 83.8% | 7.8ppt | 327 | 26% | 28% |
| Singapore | 64.8% | 65.9% | -1.1ppt | 173 | 7% | 5% |
| Malaysia | 65.1% | 67.2% | -2.1ppt | 170 | 6% | 10% |
| Mainland China | 50.3% | 67.4% | -17.1ppt | 601 | 7% | 14% |
| Others markets | 28.7% | 29.1% | -0.4ppt | 212 | 2% | 8% |
| Total VONB | 50.8% | 55.2% | -4.4ppt | 2,029 | 32% | 37% |
| EV per share (US\$) | | | | 5.89 | 0.5% | |
| OPAT per share (US\$) | | | | 0.28 | 3.8% | |

*AER= actual exchange rate, CER= constant exchange rate

Source: AIA., UOB Kay Hian

RESULTS

- **1H23 VONB in line.** AlA's value of new business (VONB) reached US\$2,029m in 1H23, a 32% yoy increase on AER basis, representing 52% of our full-year VONB forecast of US\$4,197m. The VONB of AIA is in line with our estimates and 5% above consensus'. This is driven by more than double the growth in Hong Kong following the return of mainland China visitors (MCV) and double-digit growth in Mainland China, ASEAN and Tata AIA Life in India.
- VONB margin shed 4.4ppt yoy to 50.8% in 1H23 and fell below 50% in 2Q23 due to unfavorable change in product mix. The margin compression was mainly due to the growth of low-margin long-term savings product sales to MCV in Hong Kong and an increase in sales via bancassurance channel and long-term savings products within mainland China. To provide a quantifiable breakdown, 5.1ppt of margin reduction is attributed to changes in product mix and 1.4ppt is due to a shift in channel mix. We expect the product mix changes in coming quarters to continue until the Fed starts cutting rates and reducing the attractiveness of participating products to Chinese customers.

KEY FINANCIALS

| Year to 31 Dec (US\$m) | 2021 | 2022 | 2023F | 2024F | 2025F |
|----------------------------|---------|--------|---------|---------|---------|
| Gross written premiums | 37,123 | 36,519 | 38,710 | 41,033 | 43,495 |
| Net earned premiums | 34,444 | 33,912 | 35,712 | 37,525 | 39,391 |
| Underwriting profit/(loss) | (3,596) | 16,287 | (2,635) | (3,725) | (4,985) |
| Net profit (rep./act.) | 7,488 | 352 | 7,974 | 8,550 | 9,195 |
| Net profit (adj.) | 7,488 | 352 | 7,974 | 8,550 | 9,195 |
| EPS (US\$ cent) | 62.0 | 2.9 | 66.0 | 70.8 | 76.1 |
| PE (x) | 14.4 | 306.1 | 13.5 | 12.6 | 11.7 |
| *P/EV (x) | 1.5 | 1.5 | 1.5 | 1.5 | 1.4 |
| Dividend yield (%) | 2.1 | 2.2 | 2.3 | 2.4 | 2.5 |
| Combined ratio (%) | 0.0 | 0.0 | 0.0 | 1.0 | 2.0 |
| ROE (%) | 12.1 | 0.6 | 15.1 | 14.6 | 14.3 |
| Consensus net profit | - | - | 6,810 | 7,650 | 8,377 |
| UOBKH/Consensus (x) | - | - | 1.17 | 1.12 | 1.10 |

Source: AIA Group Ltd, Bloomberg, UOB Kay Hian

*P/EV: Price/Embedded Value

BUY

(Maintained)

| Share Price | HK\$69.95 |
|--------------|-------------|
| Target Price | HK\$95.00 |
| Upside | +35.8% |
| (Previous TP | HK\$104.65) |

COMPANY DESCRIPTION

AIA Group limited provides life insurance products and services. The company offers life, medical, and health protection and savings insurance products. AIA Group serves customers worldwide

STOCK DATA

| GICS sector | Financials |
|---------------------------------|------------|
| Bloomberg ticker: | 1299 HK |
| Shares issued (m): | 11,527.3 |
| Market cap (HK\$m): | 806,334.4 |
| Market cap (US\$m): | 102,827.8 |
| 3-mth avg daily t'over (US\$m): | 219.6 |
| | |

Price Performance (%)

| 52-week high/low | | | HK\$91.35/HK\$57 | |
|------------------|--------------|--------|------------------|--------|
| 1mth | 3mth | 6mth | 1yr | YTD |
| (11.0) | (10.7) | (13.7) | (6.8) | (19.4) |
| Major Sha | areholders | | | % |
| - | | | | - |
| FY23 NAV/ | Share (US\$) | | | 4.62 |

FY23 Solvency Ratio (%)

PRICE CHART



Source: Bloomberg

ANALYST(S)

Greater China Research Team +852 2236 6799 reseachhk@uobkayhian.com.hk

UOBKayHian

Regional Morning Notes

• Interim dividend of HK\$0.42 per share was declared, indicating a 5% yoy increase. In addition to regular dividends, AIA's ongoing US\$10b share buy-back programme has to date returned US\$5.5b to shareholders, reducing the outstanding share by 5% since launching in Mar 22.

STOCK IMPACT

- Hong Kong VONB at 70% of pre-pandemic level. Hong Kong delivered strong results in 1H23 by doubling VONB, mainly driven by increased demand from MCV and double-digit growth from domestic customers. The pent-up demand from MCV was not evident in 1H23 and we only saw moderate recovery as the number of MCVs in 2Q23 was around 50% that seen in 2019. However, some positive signs such as increase in July MCV count to 70% of pre-pandemic level suggest that the trend of MCV returns may persist in 2H23.
- Growth momentum in China gains traction. AIA China's performance was below our expectations of 30% growth as we only saw 14%/7% yoy growth in VONB on CER/AER basis. This is because AIA China adopts a more cautious approach in selling whole life insurance products with 3.5% guaranteed rate compared with its domestic life insurer peers. Despite that, we are still optimistic about AIA China's expansion plan and future growth, given few catalysts in place such as: a) launch of new operations in few provinces, b) increasing agent productivity, and c) incremental growth from strategic bancassurance partnerships through PSBC and BEA. Additionally, AIA China may also face less growth pressure after the suspension of 3.5% whole life insurance products.
- ASEAN market insured company resilience growth in 1H23. The ASEAN region is a key growth engine for AIA and accounted for one-third of total VONB in 1H23. AIA have delivered aggregate VONB growth of 16%, and continue to rank first in ASEAN by new business sales. AIA Thailand achieved a significant 26% yoy VONB growth, supported by its leading Premier Agency strategy and Financial Adviser Programme. Moving forward, we believe that AIA may continue to lead in this region by leveraging its unrivalled distribution multi-channel strategy.
- CSM base grew 19% yoy in 1H23 to US\$54,858m before variances and others, exchange rates and release. Like VONB, new business contractual service margin (CSM) grew by 14%, driven by the strong sales growth achieved across AIA's geographical segments. The CSM release rate is slightly higher than last year (9.7% in 1H23 vs 9.5% in 1H22), due to the addition of new businesses in Hong Kong with a higher CSM release rate and upselling activities for in-force business in Mainland China. AIA's new business CSM over VONB ratio remains higher than its comparable peers, representing a prudent EV measurement by the company.
- Net investment in 1H23. Net investment after expenses increased by 9% to US\$1.7b, due to higher equity asset balances and increased long-term investment return assumptions. Both investment return and fixed income yield of AIA non-par and surplus asset improved in 1H23, above the long-term return assumption. Although AIA has a wide reach in mainland China, the company's exposure to real estate and LGFV is relatively small with more than 90% of AIA China's fixed income assets invested in treasury bonds.

EARNINGS REVISION/RISK


• Reduce our 2023/24 EV per share forecast by 5% to US\$6.23/6.48. We revise our longterm VONB assumption to 57.0% and reduce our 2023/24 VONB growth forecast by 7ppt/2ppt to 17.7%/12.0% after considering the deterioration of VONB margin and lower growth in mainland China.

VALUATION/RECOMMENDATION

• Maintain BUY with a lower target price of HK\$95.00, to factor in lower VONB margin and VONB growth assumptions. We roll over to 2024 valuation and our new target price is pegged to 2024 P/EV 1.88x.


Friday, 25 August 2023

AIA VONB MARGIN, ANP AND VONB YOY GROWTH




Source: AIA, UOB Kay Hian

AIA VONB (QUARTER BASIS)




Source: AIA, UOB Kay Hian

AIA PRODUCT MIX



Source: AIA, UOB Kay Hian

AIA DISTRIBUTION CHANNEL MIX



Source: AIA, UOB Kay Hian

AIA AND PEERS CSM INDICATORS COMPARISON

| End of 2022 | AIA* | Pru | Ping An | | |
|--------------------------------|------|------|---------|--|--|
| CSM Release Rate (%) | 9.7 | 10.0 | 9.0 | | |
| New CSM over NBV (x) | 1.7 | 1.0 | 1.2 | | |
| * As disclosed in 1H23 results | | | | | |

Source: Companies, UOB Kay Hian

UOBKayHian

Regional Morning Notes

Friday, 25 August 2023

| PROFIT & LOSS | | | | |
|-------------------------------|----------|----------|----------|----------|
| Year to 31 Dec (US\$m) | 2022 | 2023F | 2024F | 2025F |
| Gross written premiums | 36,519 | 38,710 | 41,033 | 43,495 |
| Premium ceded to reinsurers | (2,607) | (2,998) | (3,508) | (4,104) |
| Net earned premiums | 33,912 | 35,712 | 37,525 | 39,391 |
| Claims and insurance benefits | (9,964) | (30,304) | (32,803) | (35,507) |
| G&A exp of insurance ops | (7,267) | (7,630) | (8,012) | (8,412) |
| Other exp of insurance opss | (394) | (414) | (434) | (456) |
| Underwriting profit/(loss) | 16,287 | (2,635) | (3,725) | (4,985) |
| Investment income | (15,156) | 11,473 | 13,194 | 15,173 |
| Other income | 354 | 310 | 320 | 321 |
| Pre-tax profit | 523 | 8,128 | 8,688 | 9,320 |
| Tax | (171) | (154) | (139) | (125) |
| Net profit | 352 | 7,974 | 8,550 | 9,195 |
| Net profit (adj.) | 352 | 7,974 | 8,550 | 9,195 |

| Year to 31 Dec (US\$m) | 2022 | 2023F | 2024F | 2025F |
|--------------------------------------|---------|----------|---------|---------|
| Cash | 4,490 | 4,266 | 3,839 | 3,455 |
| Loans and advances | 9,590 | 9,878 | 10,174 | 10,480 |
| Investments (equity & fixed inc) | 259,084 | 246,361 | 291,044 | 345,560 |
| Reinsurers' share of ins liabilities | 4,741 | 5,216 | 6,207 | 7,386 |
| Associates & JVs | 645 | 632 | 638 | 645 |
| Fixed assets (incl prop) | 2,607 | 2,555 | 2,580 | 2,606 |
| Other assets | 42,984 | 41,046 | 43,219 | 45,523 |
| Total assets | 324,141 | 309,953 | 357,702 | 415,654 |
| Assets sold (repo agreement) | 1,509 | 1,433 | 1,362 | 1,293 |
| Insurance contract liabilties | 263,610 | 275,569 | 302,313 | 331,708 |
| Other liabilities | 8,742 | (23,362) | (7,751) | 14,915 |
| Total liabilities | 273,861 | 253,640 | 295,924 | 347,917 |
| Shareholders' funds | 49,804 | 55,826 | 61,283 | 67,232 |
| Minority interest - accumulated | 476 | 486 | 496 | 505 |
| Total equity & liabilities | 324,141 | 309,953 | 357,702 | 415,654 |

OPERATING RATIOS

| Year to 31 Dec (%) | 2022 | 2023F | 2024F | 2025F |
|--------------------------------------|-------|-------|-------|-------|
| Capital-related | | | | |
| Shareholders' funds/total assets | 15.4 | 18.0 | 17.1 | 16.2 |
| Total Assets/equity (x) | 6.5 | 5.6 | 5.8 | 6.2 |
| | | | | |
| Liquidity | | | | |
| Liquid assets/short-term liabilities | 127.2 | 118.1 | 108.2 | 99.2 |
| Liquid assets/total assets | 5.2 | 5.4 | 4.6 | 3.9 |
| | | | | |
| Valuation (%) | | | | |
| P/EV (x) | 1.5 | 1.5 | 1.5 | 1.4 |
| NB multiple (x) | 0.0 | 0.0 | 0.0 | 0.0 |
| Adjusted P/E (x) | 306.1 | 13.5 | 12.6 | 11.7 |
| Dividend Yield | 2.2 | 2.3 | 2.4 | 2.5 |
| Payout ratio | 665.5 | 30.8 | 30.2 | 29.5 |

KEY METRICS

BALANCE SHEET

| Year to 31 Dec (%) | 2022 | 2023F | 2024F | 2025F |
|-------------------------|--------|---------|-------|-------|
| Growth | | | | |
| Gross premiums, yoy chg | (1.6) | 6.0 | 6.0 | 6.0 |
| Net profit, yoy chg | (95.3) | 2,165.4 | 7.2 | 7.5 |
| Profitability | | | | |
| Loss ratio | 0.0 | 0.0 | 1.0 | 2.0 |
| Expense ratio | 0.0 | 0.0 | 0.0 | 0.0 |
| Combined ratio | 0.0 | 0.0 | 1.0 | 2.0 |
| Reported ROE | 0.6 | 15.1 | 14.6 | 14.3 |
| Adjusted ROE | 0.6 | 15.1 | 14.6 | 14.3 |
| | | | | |

Footnotes: FYP: first year premium; EV: embedded value; NB: new business; NBM: new business margin; APE: annual premium equivalent.



Regional Morning Notes

Friday, 25 August 2023

Disclosures/Disclaimers

This report is prepared by UOB Kay Hian Private Limited ("UOBKH"), which is a holder of a capital markets services licence and an exempt financial adviser in Singapore.

This report is provided for information only and is not an offer or a solicitation to deal in securities or to enter into any legal relations, nor an advice or a recommendation with respect to such securities.

This report is prepared for general circulation. It does not have regard to the specific investment objectives, financial situation and the particular needs of any recipient hereof. Advice should be sought from a financial adviser regarding the suitability of the investment product, taking into account the specific investment objectives, financial situation or particular needs of any person in receipt of the recommendation, before the person makes a commitment to purchase the investment product.

This report is confidential. This report may not be published, circulated, reproduced or distributed in whole or in part by any recipient of this report to any other person without the prior written consent of UOBKH. This report is not directed to or intended for distribution to or use by any person or any entity who is a citizen or resident of or located in any locality, state, country or any other jurisdiction as UOBKH may determine in its absolute discretion, where the distribution, publication, availability or use of this report would be contrary to applicable law or would subject UOBKH and its connected persons (as defined in the Financial Advisers Act, Chapter 110 of Singapore) to any registration, licensing or other requirements within such jurisdiction.

The information or views in the report ("Information") has been obtained or derived from sources believed by UOBKH to be reliable. However, UOBKH makes no representation as to the accuracy or completeness of such sources or the Information and UOBKH accepts no liability whatsoever for any loss or damage arising from the use of or reliance on the Information. UOBKH and its connected persons may have issued other reports expressing views different from the Information and all views expressed in all reports of UOBKH and its connected persons are subject to change without notice. UOBKH reserves the right to act upon or use the Information at any time, including before its publication herein.

Except as otherwise indicated below, (1) UOBKH, its connected persons and its officers, employees and representatives may, to the extent permitted by law, transact with, perform or provide broking, underwriting, corporate finance-related or other services for or solicit business from, the subject corporation(s) referred to in this report; (2) UOBKH, its connected persons and its officers, employees and representatives may also, to the extent permitted by law, transact with, perform or provide broking or other services for or solicit business from, other persons in respect of dealings in the securities referred to in this report or other investments related thereto; (3) the officers, employees and representatives of UOBKH may also serve on the board of directors or in trustee positions with the subject corporation(s) referred to in this report. (All of the foregoing is hereafter referred to as the "Subject Business"); and (4) UOBKH may otherwise have an interest (including a proprietary interest) in the subject corporation(s) referred to in this report.

As of the date of this report, no analyst responsible for any of the content in this report has any proprietary position or material interest in the securities of the corporation(s) which are referred to in the content they respectively author or are otherwise responsible for.

IMPORTANT DISCLOSURES FOR U.S. PERSONS

This research report was prepared by UOBKH, a company authorized, as noted above, to engage in securities activities in Singapore. UOBKH is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution by UOBKH (whether directly or through its US registered broker dealer affiliate named below) to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act"). All US persons that receive this document by way of distribution from or which they regard as being from UOBKH by their acceptance thereof represent and agree that they are a major institutional investor and understand the risks involved in executing transactions in securities.

Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through UOB Kay Hian (U.S.) Inc ("UOBKHUS"), a registered brokerdealer in the United States. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through UOBKH.

UOBKHUS accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to and intended to be received by a U.S. person other than a major U.S. institutional investor.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and may not be an associated person of UOBKHUS and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

UOBKayHian

Regional Morning <u>Notes</u>

Friday, 25 August 2023

Analyst Certification/Regulation AC

Each research analyst of UOBKH who produced this report hereby certifies that (1) the views expressed in this report accurately reflect his/her personal views about all of the subject corporation(s) and securities in this report; (2) the report was produced independently by him/her; (3) he/she does not carry out, whether for himself/herself or on behalf of UOBKH or any other person, any of the Subject Business involving any of the subject corporation(s) or securities referred to in this report; and (4) he/she has not received and will not receive any compensation that is directly or indirectly related or linked to the recommendations or views expressed in this report or to any sales, trading, dealing or corporate finance advisory services or transaction in respect of the securities in this report. However, the compensation received by each such research analyst is based upon various factors, including UOBKH's total revenues, a portion of which are generated from UOBKH's business of dealing in securities.

Reports are distributed in the respective countries by the respective entities and are subject to the additional restrictions listed in the following table.

| General | This report is not intended for distribution, publication to or use by any person or entity who is a citizen or resident of or located in any country or jurisdiction where the distribution, publication or use of this report would be contrary to applicable law or regulation. |
|--|---|
| Hong Kong | This report is distributed in Hong Kong by UOB Kay Hian (Hong Kong) Limited ("UOBKHHK"), which is regulated by the Securities and Futures Commission of Hong Kong. Neither the analyst(s) preparing this report nor his associate, has trading and financial interest and relevant relationship specified under Para. 16.4 of Code of Conduct in the listed corporation covered in this report. UOBKHHK does not have financial interests and business relationship specified under Para. 16.5 of Code of Conduct with the listed corporation covered in this report. UOBKHHK does not have financial interests and business relationship specified under Para. 16.5 of Code of Conduct with the listed corporation covered in this report. Where the report is distributed in Hong Kong and contains research analyses or reports from a foreign research house, please note: (i) recipients of the analyses or reports are to contact UOBKHHK (and not the relevant foreign research house) in Hong Kong in respect of any matters arising from, or in connection with, the analysis or report; and (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Hong Kong who is not a professional investor, or institutional investor, UOBKHHK accepts legal responsibility for the contents of the analyses or reports only to the extent required by law. |
| Indonesia | This report is distributed in Indonesia by PT UOB Kay Hian Sekuritas, which is regulated by Financial Services Authority of Indonesia ("OJK"). Where the report is distributed in Indonesia and contains research analyses or reports from a foreign research house, please note recipients of the analyses or reports are to contact PT UOBKH (and not the relevant foreign research house) in Indonesia in respect of any matters arising from, or in connection with, the analysis or report. |
| Malaysia | Where the report is distributed in Malaysia and contains research analyses or reports from a foreign research house, the recipients of the analyses or reports are to contact UOBKHM (and not the relevant foreign research house) in Malaysia, at +603-21471988, in respect of any matters arising from, or in connection with, the analysis or report as UOBKHM is the registered person under CMSA to distribute any research analyses in Malaysia. |
| Singapore | This report is distributed in Singapore by UOB Kay Hian Private Limited ("UOBKH"), which is a holder of a capital markets services licence and an exempt financial adviser regulated by the Monetary Authority of Singapore.Where the report is distributed in Singapore and contains research analyses or reports from a foreign research house, please note: (i) recipients of the analyses or reports are to contact UOBKH (and not the relevant foreign research house) in Singapore in respect of any matters arising from, or in connection with, the analysis or report; and (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Singapore who is not an accredited investor, expert investor or institutional investor, UOBKH accepts legal responsibility for the contents of the analyses or reports only to the extent required by law. |
| Thailand | This report is distributed in Thailand by UOB Kay Hian Securities (Thailand) Public Company Limited, which is regulated by the Securities and Exchange Commission of Thailand. |
| United Kingdom | This report is being distributed in the UK by UOB Kay Hian (U.K.) Limited, which is an authorised person in the meaning of the Financial Services and Markets Act and is regulated by The Financial Conduct Authority. Research distributed in the UK is intended only for institutional clients. |
| United States of America ('U.S.') | This report cannot be distributed into the U.S. or to any U.S. person or entity except in compliance with applicable U.S. laws and regulations. It is being distributed in the U.S. by UOB Kay Hian (US) Inc, which accepts responsibility for its contents. Any U.S. person or entity receiving this report and wishing to effect transactions in any securities referred to in the report should contact UOB Kay Hian (US) Inc. directly. |

Copyright 2023, UOB Kay Hian Pte Ltd. All rights reserved.

http://research.uobkayhian.com

RCB Regn. No. 197000447W